Unbound Cloxacillin Concentrations During Continuous Infusion

Phase 4

Not yet recruiting

• Conditions: Staphylococcal Infections

• Registration Number: NCT06848387
• Lead Sponsor: Emeli Månsson

Brief Summary

Cloxacillin is the first-line choice for the treatment of severe infections caused by the bacterium Staphylococcus aureus in Sweden. Over the past year, cloxacillin is increasingly administred through continuous infusion. In this study, the free (unbound) concentration of cloxacillin when administered as a continuous infusion will be measured to ensure that the free concentration is neither too high nor too low. A PK/PD model will be developed to predict which dosage of cloxacillin is appropriate for an individual based on age, gender, kidney function, and serum-protein level.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-01-15
• Study First Submitted QC: 2025-02-23
• Study First Posted: 2025-02-27
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-14
• Last Update Posted: 2025-05-18
• Study Start: 2025-12
• Primary Completion: 2026-12
• Study Completion: 2027-12

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

• Age 18 years or older
• Treating physician has decided to start continuous infusion of cloxacillin

Exclusion Criteria

• Unwilling or unable to provide written informed consent

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Free (unbound) cloxacillin concentration	From enrollment to end of follow up at 48 hours